A detailed history of E Fund Management Co., Ltd. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 4,229 shares of VRTX stock, worth $2.01 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
4,229
Previous 4,351 2.8%
Holding current value
$2.01 Million
Previous $1.77 Million 0.17%
% of portfolio
0.11%
Previous 0.11%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$407.69 - $446.08 $49,738 - $54,421
-122 Reduced 2.8%
4,229 $1.77 Million
Q4 2023

Feb 06, 2024

SELL
$343.0 - $410.68 $26,754 - $32,033
-78 Reduced 1.76%
4,351 $1.77 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $148,122 - $158,757
438 Added 10.97%
4,429 $1.54 Million
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $144,318 - $161,526
-459 Reduced 10.31%
3,991 $1.4 Million
Q1 2023

May 11, 2023

SELL
$283.23 - $323.1 $50,981 - $58,158
-180 Reduced 3.89%
4,450 $1.4 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $2.01 Million - $2.26 Million
-7,018 Reduced 60.25%
4,630 $1.34 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $1.81 Million - $2.01 Million
6,592 Added 130.38%
11,648 $3.37 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $126,643 - $157,684
539 Added 11.93%
5,056 $1.43 Million
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $21,920 - $25,836
99 Added 2.24%
4,517 $1.18 Million
Q4 2021

Feb 11, 2022

SELL
$177.01 - $223.45 $29,737 - $37,539
-168 Reduced 3.66%
4,418 $970,000
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $76,365 - $85,458
421 Added 10.11%
4,586 $832,000
Q1 2021

May 12, 2021

BUY
$207.02 - $241.31 $862,238 - $1.01 Million
4,165 New
4,165 $895,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.